8-K: Alector Announces CFO Transition and Key Leadership Appointments Amidst Clinical Trial Progress

Alector, Inc. announced the resignation of its Chief Financial Officer, Dr. Marc Grasso, effective June 20, 2025, with Neil Berkley appointed Interim CFO and Grace Wong-Sarad as Principal Accounting Officer, while also confirming progress in its late-stage clinical programs and successful stockholder votes.

Summary

• Dr. Marc Grasso will resign as Chief Financial Officer of Alector, Inc. effective June 20, 2025, to pursue other opportunities.
• Neil Berkley, current Chief Business Officer, will assume the role of Interim Chief Financial Officer and principal financial officer, effective upon Dr. Grasso's resignation.
• Grace Wong-Sarad, Vice President, Accounting, will serve as the principal accounting officer, effective upon Dr. Grasso's resignation.
• Alector reported a cash runway extending into the second half of 2027.
• The company remains on track to report topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a GRN gene mutation (FTD-GRN) in Q4 2025.
• Enrollment has been completed in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease (AD) in April 2025.
• Alector held its 2025 annual meeting of stockholders on June 11, 2025, where all three proposals were approved.
• Stockholders elected Class I director nominees Dr. Arnon Rosenthal and Dr. Paula Hammond to serve until the 2028 annual meeting.
• The appointment of Ernst & Young LLP as the independent registered accounting firm for fiscal year ending December 31, 2025, was ratified.
• Stockholders approved, on a non-binding advisory basis, the compensation of Alector's named executive officers (Say-on-Pay vote).

Sentiment

Score: 7

Explanation: The sentiment is largely positive due to the strong cash runway, significant progress in late-stage clinical trials, and successful stockholder votes. While there is a CFO transition, it is framed as amicable and well-managed with experienced internal appointments, including retention bonuses to ensure continuity. The focus on pipeline advancement and proprietary technology also contributes to a positive outlook.

Positives

• Alector has a strong cash runway extending into the second half of 2027, providing financial stability for ongoing operations and clinical programs.
• The company is on track to report topline data from the pivotal INFRONT-3 Phase 3 trial for FTD-GRN in Q4 2025, indicating progress in a key late-stage clinical program.
• Enrollment for the PROGRESS-AD Phase 2 trial for early Alzheimer's disease was successfully completed in April 2025, marking a significant milestone.
• The appointment of Neil Berkley as Interim CFO leverages his extensive experience in corporate and business development across pharma and biotech, ensuring continuity and strategic insight.
• Grace Wong-Sarad's promotion to principal accounting officer recognizes her long-standing tenure and expertise within Alector's finance team, ensuring a smooth transition in financial reporting.
• All proposals at the 2025 annual meeting of stockholders were approved, including the election of directors, ratification of auditors, and the Say-on-Pay vote, indicating strong shareholder support and stable corporate governance.

Negatives

• The departure of a Chief Financial Officer, even if amicable, can introduce a period of transition and potential uncertainty regarding financial leadership.

Risks

• Forward-looking statements are subject to numerous risks and uncertainties, including those related to business plans, business strategy, product candidates, technology platforms, preclinical studies, clinical trials, anticipated timing and details of data release, expected milestones, collaborations, interactions with regulatory authorities, and financial and cash guidance.
• Actual results for Alector could differ materially from those contained in forward-looking statements due to various factors, as detailed in Alector's Quarterly Report on Form 10-Q filed on May 8, 2025, with the SEC, and other SEC filings.

Future Outlook

Alector anticipates reporting topline data from its pivotal INFRONT-3 Phase 3 trial for latozinemab in FTD-GRN in the fourth quarter of 2025. The company has also completed enrollment for its PROGRESS-AD Phase 2 trial for AL101 in early Alzheimer's disease. Alector plans to continue strategically pursuing research and preclinical programs, including ADP037-ABC for AD and ADP050-ABC for Parkinson's disease, leveraging its proprietary Alector Brain Carrier (ABC) technology platform.

Management Comments

• "Marc has been a valuable member of our leadership team and a strong steward of the company since joining Alector in February 2022. He played a key role in strengthening our financial position and building a high-performing finance team." Arnon Rosenthal, Ph.D., CEO of Alector.
• "With cash runway into the second half of 2027, Alector is well positioned to advance our clinical, preclinical, and research programs through key inflection points." Arnon Rosenthal, Ph.D., CEO of Alector.
• "As Neil steps into the role of Interim CFO, the solid financial infrastructure established under Marc's leadership, combined with Neil's experience in corporate development and business strategy, will help ensure a smooth transition." Arnon Rosenthal, Ph.D., CEO of Alector.
• "It has been an honor to contribute to Alector's mission of developing innovative therapies for neurodegenerative diseases. I'm proud of the financial position the team has established to support the company's progress." Dr. Marc Grasso, outgoing CFO.
• "I have full confidence in Neil and the entire leadership team to guide Alector through this next phase. I remain committed to ensuring a smooth transition and wish Alector continued success in advancing its important pipeline." Dr. Marc Grasso, outgoing CFO.

Industry Context

This announcement reflects typical operational activities within the biotechnology sector, particularly for a late-stage clinical company. Management transitions are common, and the appointment of an interim CFO with strong business development experience suggests a focus on strategic partnerships and corporate growth alongside financial oversight. The continued progress in neurodegenerative disease clinical trials (FTD, AD) aligns with the industry's ongoing efforts to address significant unmet medical needs in this therapeutic area. The emphasis on a proprietary blood-brain barrier technology platform (ABC) highlights the industry trend towards innovative drug delivery methods to improve efficacy for central nervous system disorders.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders:** The successful annual meeting votes indicate stable corporate governance and shareholder alignment. The management transition is presented as smooth, aiming to maintain confidence. Progress in clinical trials could positively impact future share value.
• **Employees:** The appointments of Neil Berkley and Grace Wong-Sarad to expanded roles, including retention bonuses, demonstrate internal career progression and recognition. The departure of the CFO may create some internal adjustments.
• **Patients:** Continued progress in late-stage clinical trials for neurodegenerative diseases offers hope for new therapeutic options for conditions like FTD-GRN and Alzheimer's disease.
• **Creditors/Investors:** The stated cash runway into the second half of 2027 provides financial assurance regarding the company's ability to fund operations and development programs.

Next Steps

• Report topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN in Q4 2025.
• Continue advancing clinical, preclinical, and research programs, including ADP037-ABC and ADP050-ABC.
• Neil Berkley and Grace Wong-Sarad will assume their new roles as Interim CFO and Principal Accounting Officer, respectively, effective June 20, 2025.
• Grace Wong-Sarad's base salary will increase as of June 30, 2025.
• Neil Berkley and Grace Wong-Sarad will receive retention bonuses in December 2025.

Key Dates

Keywords

Biotechnology, Neurodegeneration, SEC Filing, 8-K, CFO, Chief Financial Officer, Interim CFO, Clinical Trials, Phase 3, Phase 2, Alzheimer's Disease, Frontotemporal Dementia, Parkinson's Disease, Drug Development, Corporate Governance, Stockholder Meeting, Cash Runway, Alector Brain Carrier, ALEC